Women with gynecological cancer have more treatment options than ever. Currently, Duke has 15 clinical trials open for women with gynecologic cancers, including ovarian, endometrial, or cervical cancer.
Susan Dent, MD, FRCPC, joined Duke Cancer Institute in September 2018 to co-lead Duke’s efforts in cardio-oncology—a discipline focused on the intersection of heart disease and cancer. She'll also serve as professor of medicine and associate director of breast cancer clinical research.
An increased survival benefit for black men with advanced prostate cancer and a stronger response to hormone therapy were the centerpieces of racial disparity studies presented by researchers from Duke’s Prostate & Urologic Cancer Center.
Duke Cancer Institute constellates the world-class resources of Duke University, Duke Health and the Duke Comprehensive Cancer Center into a collaborative powerhouse. We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war.